Developer docs
API playgroundTry for free, no card

Search company profiles

Mobidiag

Full company profile

uuid0002vor

Namestring
Mobidiag
Legal namestring
Mobidiag
Websiteurl
mobidiag.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Mobidiag is a Finnish molecular diagnostics company, founded in 2000 and headquartered in Espoo, Finland, that developed and commercialized rapid diagnostic solutions for infectious disease detection. The company's core offering centered on the proprietary Novodiag® System, a molecular diagnostics platform designed for automated detection of infectious pathogens including gastrointestinal, respiratory, and sexually transmitted infections. The platform utilized random-access molecular testing technology to deliver Walk-Away simplicity for clinical laboratories, with the Novodiag® Direct cartridge-based sub-product enabling direct pathogen detection from patient samples without extensive sample preparation, providing results in approximately 1-2 hours.

The company's go-to-market targeted healthcare providers and diagnostic laboratories requiring rapid infectious disease testing, with particular focus on the STD diagnostics segment aligned with a market projected to reach $17.52 billion by 2030. Mobidiag operated as a venture-backed private company, raising approximately $74 million across multiple funding rounds between 2016 and 2020 from investors including the European Investment Bank, Business Finland, Autobio Diagnostics, and Springvest. The company was acquired by Hologic, a US-based women's health diagnostics company, though the Novodiag product line was subsequently discontinued from Hologic's molecular diagnostics portfolio, suggesting a complex post-acquisition outcome. No publicly disclosed pricing, revenue figures, or detailed customer information is available in the provided sources.

Mobidiag's technology was differentiated by its novel method architecture for automated molecular diagnostics, emphasizing point-of-need testing capabilities and rapid turnaround times compared to traditional diagnostic methods. The cartridge-based consumable model would have generated recurring revenue from installed instrument bases in clinical settings, though the specific revenue mechanics, pricing structure, and commercial scale are not documented in available sources.

Short descriptiontext

Mobidiag is a Finnish molecular diagnostics company that developed the proprietary Novodiag platform for automated, rapid detection of infectious diseases including gastrointestinal, respiratory, and sexually transmitted infections, serving clinical laboratories and healthcare providers before being acquired by Hologic.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEspoo, Finland
HQ citystring
Espoo
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
molecular diagnostics, infectious disease testing, rapid pathogen detection, diagnostic cartridge systems, clinical laboratory instruments
Industry4 codes
PRIMARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
Social media profiles2 records
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Novodiag
Description

Molecular diagnostics platform for rapid infectious disease testing

hologic.com
Core offering1 text field

Mobidiag develops and commercializes the Novodiag molecular diagnostics platform for rapid detection of infectious diseases, including gastrointestinal, respiratory, and sexually transmitted infections. The portfolio includes the Novodiag System instrument and Novodiag Direct cartridge-based tests, which provide automated random-access molecular testing with results in approximately 1-2 hours directly from patient samples.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mobidiag offers a unified molecular diagnostics platform centered on the Novodiag® system. The portfolio consists of the core Novodiag® instrument platform and the Novodiag® Direct cartridge-based test. The Novodiag® Direct tests are designed for rapid, point-of-need detection of infectious pathogens including gastrointestinal, respiratory, and sexually transmitted infections. The system utilizes random-access molecular testing technology enablingWalk-Away simplicity for clinical laboratories.

Product and service2 records
1Novodiag System
CategoryMolecular Diagnostics Instrument
Description

A rapid molecular diagnostic testing platform designed for automated detection of infectious diseases, including gastrointestinal, respiratory, and sexually transmitted infections. Built on random-access molecular testing technology providing walk-away simplicity for clinical laboratories.

2Novodiag Direct
CategoryMolecular Diagnostics Cartridge Test
Description

A cartridge-based molecular test enabling direct detection of pathogens from patient samples without extensive sample preparation, providing results in approximately 1-2 hours. Targeted at clinical laboratories and point-of-need settings for rapid infectious disease diagnosis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Seegene develops multiplex molecular diagnostics with a high-menu syndromic approach similar to Mobidiag's strategy, serving respiratory, GI, and STI testing markets.

TypeEmerging player
Description

T2 develops molecular diagnostics for infectious disease, including sepsis and resistant pathogens, partially overlapping with Mobidiag's infectious disease focus.

TypeDirect peer
Description

Cepheid's GeneXpert system is the leading molecular POCT platform for infectious disease detection — same product category, same customer base (clinical labs and hospitals), and same cartridge-based assay model as Mobidiag's Novodiag.

TypeDirect peer
Description

BioFire FilmArray panels are a direct competitor in syndromic molecular infectious disease testing (respiratory, GI), with comparable turnaround times and a similar clinical-laboratory go-to-market.

TypeBroad incumbent
Description

Roche's cobas Liat system is a molecular POCT platform for infectious disease, and Roche also owns GenMark — directly comparable technology in the same point-of-care molecular diagnostics category.

6Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's ID NOW and m-PIMA platforms compete in rapid molecular POCT for infectious diseases, addressing the same hospitals, urgent-care, and clinical-lab customers as Mobidiag.

TypeBroad incumbent
Description

Hologic acquired Mobidiag and operates the Panther Fusion molecular diagnostics system, making it both an acquirer and a peer in the molecular infectious disease testing space.

TypeBroad incumbent
Description

QIAGEN offers sample-to-result molecular testing solutions (QIAstat-Dx) for syndromic infectious disease detection, directly comparable to Mobidiag's cartridge-based approach.

TypeBroad incumbent
Description

QuidelOrtho markets Sofia and other rapid infectious disease diagnostics and is expanding into molecular — overlapping with Mobidiag's respiratory and STI testing focus.

TypeEmerging player
Description

Curetis developed the Unyvero molecular cartridge-based platform for severe infectious disease diagnostics — a comparable European molecular Dx peer with a similar cartridge/instrument model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mobidiag

Molecular Diagnosticsmobidiag.com

Mobidiag is a Finnish molecular diagnostics company that developed the proprietary Novodiag platform for automated, rapid detection of infectious diseases including gastrointestinal, respiratory, and sexually transmitted infections, serving clinical laboratories and healthcare providers before being acquired by Hologic.

What Mobidiag does

Mobidiag is a Finnish molecular diagnostics company, founded in 2000 and headquartered in Espoo, Finland, that developed and commercialized rapid diagnostic solutions for infectious disease detection. The company's core offering centered on the proprietary Novodiag® System, a molecular diagnostics platform designed for automated detection of infectious pathogens including gastrointestinal, respiratory, and sexually transmitted infections. The platform utilized random-access molecular testing technology to deliver Walk-Away simplicity for clinical laboratories, with the Novodiag® Direct cartridge-based sub-product enabling direct pathogen detection from patient samples without extensive sample preparation, providing results in approximately 1-2 hours.

The company's go-to-market targeted healthcare providers and diagnostic laboratories requiring rapid infectious disease testing, with particular focus on the STD diagnostics segment aligned with a market projected to reach $17.52 billion by 2030. Mobidiag operated as a venture-backed private company, raising approximately $74 million across multiple funding rounds between 2016 and 2020 from investors including the European Investment Bank, Business Finland, Autobio Diagnostics, and Springvest. The company was acquired by Hologic, a US-based women's health diagnostics company, though the Novodiag product line was subsequently discontinued from Hologic's molecular diagnostics portfolio, suggesting a complex post-acquisition outcome. No publicly disclosed pricing, revenue figures, or detailed customer information is available in the provided sources.

Mobidiag's technology was differentiated by its novel method architecture for automated molecular diagnostics, emphasizing point-of-need testing capabilities and rapid turnaround times compared to traditional diagnostic methods. The cartridge-based consumable model would have generated recurring revenue from installed instrument bases in clinical settings, though the specific revenue mechanics, pricing structure, and commercial scale are not documented in available sources.

Mobidiag firmographics

Firmographics
Name
Mobidiag
Legal name
Mobidiag
Website
https://mobidiag.com
Company type
Private
Founded year
2000
Operating status
Acquired
Headcount range
51–100 employees
Short description
Mobidiag is a Finnish molecular diagnostics company that developed the proprietary Novodiag platform for automated, rapid detection of infectious diseases including gastrointestinal, respiratory, and sexually transmitted infections, serving clinical laboratories and healthcare providers before being acquired by Hologic.
Ownership category
akta.pro rank

Mobidiag industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAOAI
Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Molecular diagnostics
  • Infectious disease testing
  • Rapid pathogen detection
  • Diagnostic cartridge systems
  • Clinical laboratory instruments

Where Mobidiag is headquartered

Location

Headquarters

HQ city
Espoo
HQ country
Finland
HQ region
Europe

Markets served

Mobidiag business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Mobidiag product offering

Product offering

Core offering

Mobidiag develops and commercializes the Novodiag molecular diagnostics platform for rapid detection of infectious diseases, including gastrointestinal, respiratory, and sexually transmitted infections. The portfolio includes the Novodiag System instrument and Novodiag Direct cartridge-based tests, which provide automated random-access molecular testing with results in approximately 1-2 hours directly from patient samples.

Product overview

Mobidiag offers a unified molecular diagnostics platform centered on the Novodiag® system. The portfolio consists of the core Novodiag® instrument platform and the Novodiag® Direct cartridge-based test. The Novodiag® Direct tests are designed for rapid, point-of-need detection of infectious pathogens including gastrointestinal, respiratory, and sexually transmitted infections. The system utilizes random-access molecular testing technology enablingWalk-Away simplicity for clinical laboratories.

Differentiator

Problem solved

Functional benefit

Brands

  • Novodiag: Molecular diagnostics platform for rapid infectious disease testing

Products and services

  • Novodiag System A rapid molecular diagnostic testing platform designed for automated detection of infectious diseases, including gastrointestinal, respiratory, and sexually transmitted infections. Built on random-access molecular testing technology providing walk-away simplicity for clinical laboratories.
  • Novodiag Direct A cartridge-based molecular test enabling direct detection of pathogens from patient samples without extensive sample preparation, providing results in approximately 1-2 hours. Targeted at clinical laboratories and point-of-need settings for rapid infectious disease diagnosis.

Companies that use Mobidiag

Customer profile

Segments1 record

Ideal customer profiles2 records

Mobidiag technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Mobidiag partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights4 records

Mobidiag competitors and assessment

Company assessment

Emerging players

  • Seegene: Seegene develops multiplex molecular diagnostics with a high-menu syndromic approach similar to Mobidiag's strategy, serving respiratory, GI, and STI testing markets.
  • T2 Biosystems: T2 develops molecular diagnostics for infectious disease, including sepsis and resistant pathogens, partially overlapping with Mobidiag's infectious disease focus.
  • Curetis (OpGen): Curetis developed the Unyvero molecular cartridge-based platform for severe infectious disease diagnostics — a comparable European molecular Dx peer with a similar cartridge/instrument model.

Direct peers

  • Cepheid (Danaher): Cepheid's GeneXpert system is the leading molecular POCT platform for infectious disease detection — same product category, same customer base (clinical labs and hospitals), and same cartridge-based assay model as Mobidiag's Novodiag.
  • bioMérieux (BioFire): BioFire FilmArray panels are a direct competitor in syndromic molecular infectious disease testing (respiratory, GI), with comparable turnaround times and a similar clinical-laboratory go-to-market.

Broad incumbents

  • Roche Diagnostics: Roche's cobas Liat system is a molecular POCT platform for infectious disease, and Roche also owns GenMark — directly comparable technology in the same point-of-care molecular diagnostics category.
  • Abbott Diagnostics: Abbott's ID NOW and m-PIMA platforms compete in rapid molecular POCT for infectious diseases, addressing the same hospitals, urgent-care, and clinical-lab customers as Mobidiag.
  • Hologic: Hologic acquired Mobidiag and operates the Panther Fusion molecular diagnostics system, making it both an acquirer and a peer in the molecular infectious disease testing space.
  • QIAGEN: QIAGEN offers sample-to-result molecular testing solutions (QIAstat-Dx) for syndromic infectious disease detection, directly comparable to Mobidiag's cartridge-based approach.
  • QuidelOrtho: QuidelOrtho markets Sofia and other rapid infectious disease diagnostics and is expanding into molecular — overlapping with Mobidiag's respiratory and STI testing focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Mobidiag social profiles

Digital presence

Mobidiag financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mobidiag leadership team

Management profile

Number of profiles

Profiles3 records

Mobidiag funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mobidiag M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mobidiag

What does Mobidiag do?

Mobidiag develops and commercializes the Novodiag molecular diagnostics platform for rapid detection of infectious diseases, including gastrointestinal, respiratory, and sexually transmitted infections. The portfolio includes the Novodiag System instrument and Novodiag Direct cartridge-based tests, which provide automated random-access molecular testing with results in approximately 1-2 hours directly from patient samples.

Is Mobidiag a public or private company?

Mobidiag is a private company. It is classified as corporate owned and is currently acquired.

When was Mobidiag founded?

Mobidiag was founded in 2000. It employs 51 to 100 people.

Where is Mobidiag based?

Mobidiag is headquartered in Espoo, Finland, in the Europe region.

Who are Mobidiag's main competitors?

Emerging players on record are Seegene, T2 Biosystems and Curetis (OpGen). Direct peers are Cepheid (Danaher) and bioMérieux (BioFire). Broad incumbents are Roche Diagnostics, Abbott Diagnostics, Hologic, QIAGEN and QuidelOrtho.

Does Mobidiag have an API?

No public API is recorded for Mobidiag.

What industry is Mobidiag in?

Mobidiag's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaHologic Strengthens Diagnostics Business With $795M Mobidiag DealHologic Inc has agreed to acquire Mobidiag Oy, a Europe-based molecular diagnostic company, for an enterprise value of approximately $795 million, consisting of $714 million in cash for equity and $81 million for net debt. Mobidiag generated roughly $42 million in revenue in 2020 and operates the Amplidiag and Novodiag automated testing platforms delivering PCR-based results in 50 minutes to two hours. The acquisition is expected to close in the fourth quarter of this year, with Hologic planning to invest in assay development to drive Novodiag platform growth.BenzingaMobidiag Signs Exclusive Agreement With Pro Med Diagnostics for the Distribution of Amplidiag® and NovodiMobidiag signed an exclusive agreement with Pro Med Diagnostics to distribute its Amplidiag and Novodiag products in South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya, and Uganda. The deal expands Mobidiag's commercial footprint in Africa, a fast-growing market for diagnostic products.Business Wire BlogMobidiag announces launch of Automobi Molecular DiagnosticsMobidiag and Autobio Diagnostics launched Automobi Molecular Diagnostics, a joint venture to commercialize the Novodiag platform and infectious disease assays in Greater China. Autobio holds 65% with €8m cash, Mobidiag 35% with €4.3m. Initial activities include NMPA registration and local manufacturing facilities.PR NewswireGinolis Provides Mobidiag High Throughput Manufacturing Lines for Growing Needs of Novodiag® CartridgesGinolis Ltd has signed an agreement to provide high-throughput manufacturing lines to Mobidiag Ltd to support the production of its Novodiag® test cartridges. This partnership enables Mobidiag to scale from small-scale production to industrial volumes, addressing growing demand for rapid molecular diagnostics and antibiotic resistance testing.FinSMEsMolecular Diagnostics Company Mobidiag Signs €15m Loan with EIBMobidiag Oy, a Finnish molecular diagnostics company, signed a €15m loan with the European Investment Bank. The loan, part of the InnovFin initiative, will fund manufacturing, assay validation, and commercialization of its Novodiag products over three years. The company also develops Amplidiag multiplex tests and an automated platform.